EAGAN, Minn., Nov. 16, 2020 /PRNewswire/ -- Up to 55% of
migraine patients do not have sufficient relief with currently
available treatments.2 NURTEC™
ODT (rimegepant) can work quickly, returning patients to normal
function in as little as one hour.1 NURTEC ODT's
manufacturer, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:
BHVN), and pharmacy benefit manager Prime Therapeutics LLC (Prime)
recently entered into a value-based contract agreement to help
ensure that relief truly comes for patients.
The value-based contract seeks to offer Prime's health plan
clients financial protection from high member use of the medicine.
At the same time, it guards NURTEC ODT's price to value across the
varying acute treatment needs of migraine patients.
Gaining U.S. Food and Drug Administration (FDA) approval in
February 2020, NURTEC ODT is the
first FDA-approved drug from Biohaven. This quick-dissolving tablet
is convenient for people suffering from migraine. It can be taken
without water and is the first and only calcitonin gene-related
peptide (CGRP) receptor antagonist available in a quick-dissolve
orally disintegrating tablet (ODT) formulation.1
In February 2020, the Institute
for Clinical and Economic Review (ICER) issued a policy
recommendation report on acute treatment of migraine. The review of
NURTEC ODT and other similar treatments found the price range
"helps maximize health overall, because they do not contribute to
affordability concerns and loss of insurance."3
"Collaborative manufacturer involvement was imperative for
Biohaven and Prime to quickly agree on a value-based agreement,"
said Kelly McGrail-Pokuta, vice
president, trade relations and strategy at Prime. "Adding NURTEC
ODT to our portfolio of value-based contracts strengthens Prime's
commitment to improving outcomes for patients while lowering the
total cost of care."
"We believe NURTEC ODT can deliver relief that people with
migraine need to treat their acute attacks and get back to their
lives. Ensuring broad patient access is critical. This innovative,
outcomes-based agreement with Prime Therapeutics is a key example
of our aligned commitment to the patient," said BJ Jones, chief
commercial officer of migraine and common diseases at Biohaven.
"Prime Therapeutics, a leading national provider of pharmaceutical
benefit, is an important partner of ours as we work together to
ensure that millions of patients with migraine have access to
NURTEC ODT."
Nearly 40 million people in the U.S. suffer from
migraine4 and the World Health Organization classifies
migraine as one of the 10 most disabling medical
illnesses.5 Migraine is characterized by
debilitating attacks lasting four to 72 hours with multiple
symptoms, including pulsating headaches of moderate to severe pain
intensity that can be associated with nausea or vomiting, and/or
sensitivity to sound (phonophobia) and sensitivity to light
(photophobia).6 There is a significant unmet need for
new acute treatments as more than 90 percent of migraine sufferers
are unable to work or function normally during an attack.
- Biohaven's NURTEC™ ODT (rimegepant) Receives FDA
Approval for the Acute Treatment of Migraine in Adults. (2020,
February 27). Retrieved October 1, 2020, from
https://www.biohavenpharma.com/investors/news-events/press-releases/02-27-2020
- Lipton RB et al. Headache. 2017;57(7):1026-1040.
- ICER Issues Final Report and Policy Recommendations on Acute
Treatments for Migraine. (2020, February
25). Retrieved October 1,
2020, from
https://icer-review.org/announcements/acute_migraine_final_report/
- Burch R, Rizzoli P, Loder E. The Prevalence and Impact of
Migraine and Severe Headache in the
United States: Figures and Trends From Government Health
Studies. Headache. 2018;58(4):496-505
- GBD 2016 Headache Collaborators. Global, regional, and national
burden of migraine and tension-type headache, 1990-2016: a
systematic analysis for the Global Burden of Disease Study 2016.
Lancet Neurol 2018;17(11):954-976.
- Headache Classification Committee of the International Headache
Society (IHS). The international classification of headache
disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) makes health care work better by
helping people get the medicine they need to feel better and live
well. Prime provides total drug management solutions for health
plans, employers, and government programs including Medicare and
Medicaid. The company processes claims and offers clinical services
for people with complex medical conditions. Prime serves more than
30 million people. It is collectively owned by 18 Blue Cross and
Blue Shield Plans, subsidiaries or affiliates of those plans. For
more information visit www.primetherapeutics.com or follow
@Prime_PBM on Twitter.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a
portfolio of innovative, best-in-class therapies to improve the
lives of patients with debilitating neurological and
neuropsychiatric diseases, including rare disorders. Biohaven's
neuroinnovation portfolio includes FDA-approved
NURTEC™ ODT (rimegepant) for the acute treatment of
migraine and a broad pipeline of late-stage product candidates
across three distinct mechanistic platforms: CGRP receptor
antagonism for the acute and preventive treatment of migraine;
glutamate modulation for obsessive-compulsive disorder, Alzheimer's
disease, and spinocerebellar ataxia; and myeloperoxidase (MPO)
inhibition for multiple system atrophy and amyotrophic lateral
sclerosis. More information about Biohaven is available
at www.biohavenpharma.com.
Contact:
Denise Lecher
Public Relations Manager
612.777.5763
denise.lecher@primetherapeutics.com
View original
content:http://www.prnewswire.com/news-releases/value-based-agreement-between-prime-therapeutics-and-biohaven-aims-to-bring-nurtec-odt-acute-migraine-treatment-financial-protection-to-health-plans-301173425.html
SOURCE Prime Therapeutics LLC